Elbow Tendinopathy: When Gripping Becomes Agony

Tennis elbow, golfer's elbow, and chronic elbow tendinopathy — what the evidence actually supports, why cortisone can make the long term worse, and where regenerative medicine genuinely stands.

Start Here: What Happens If You Do Nothing

Most pages selling an elbow treatment do not open with this section. It belongs first, because without it no number further down means anything.

Lateral epicondylitis is, for the majority of people who get it, a self-limiting condition. Three independent randomised controlled trials have measured the untreated course directly:

A systematic review of 41 randomised trials and 2,672 participants reached the same conclusion from the opposite direction: for lateral epicondylalgia, no intervention was statistically favoured over corticosteroid injection at 26 weeks (SMD −0.40, 95% CI −0.67 to −0.14) and at 52 weeks (−0.31, −0.61 to −0.01)⁷.

What this means for you practically:

• If your symptoms began in the last few weeks or months, time and load management are genuinely likely to resolve them. That is not us talking you out of treatment; it is what the trials show
• The trials that measured "wait and see" still measured a full year of waiting. Eighty-three percent recovered — which also means roughly one in six did not
• The people for whom regenerative treatment is a reasonable conversation are the ones for whom that year has already passed without recovery. That is the population this page is written for, and it is a smaller group than the marketing for this condition usually implies

If you have had elbow pain for six weeks, the honest advice is a loading programme and patience. If you have had it for two years and it is costing you your work or your sport, keep reading.

The Problem

When a Handshake Becomes a Challenge

It starts small. A twinge when you lift the kettle. A sharp jab when you turn a doorknob. Before long, opening a jar feels impossible, and you find yourself apologising for a weak handshake.

Elbow tendinopathy — whether it strikes the outside (tennis elbow) or inside (golfer's elbow) — is uniquely disruptive because it attacks the movements we take completely for granted. Gripping, twisting, lifting. The foundation of hand function.

For the executive who can't hold a pen through a board meeting, the golfer whose swing sends lightning through their forearm, or the grandparent who can't lift a toddler, the frustration goes beyond pain. It's the loss of capability — and it is measurable in work participation, which is one reason the condition carries a significant socioeconomic cost².

The Cortisone Trap

Most patients follow a predictable path: physiotherapy, then anti-inflammatories, then cortisone injections. The cortisone feels miraculous — for about six weeks. Then the pain returns, often worse. Another injection. Another temporary fix.

The short-term relief is real. That is exactly what makes the pattern hard to see.

In the pooled analysis of 41 trials, corticosteroid injection had a large short-term effect on lateral epicondylalgia pain — SMD 1.44 (95% CI 1.17–1.71) versus no intervention at four weeks⁷. Anyone who tells you cortisone does nothing is wrong, and your own experience of the first six weeks is not imagined.

Then it reverses. The same analysis found no intervention favoured at 26 and 52 weeks⁷. The randomised trial evidence is blunter still:

• Coombes 2013⁶: corticosteroid injection produced lower one-year complete recovery or much improvement than a placebo injection — 83% vs 96% (RR 0.86, 99% CI 0.75–0.99) — and 1-year recurrence of 54% vs 12% (RR 0.23, 99% CI 0.10–0.51)
• Smidt 2002⁴: 92% success at six weeks for injection, falling to 69% at one year — below both physiotherapy (91%) and wait-and-see (83%)
• Bisset 2006⁵: significantly better at six weeks, then 47 of 65 initial successes subsequently regressed

Two honest qualifications, because the picture is not one-sided:

1. Serious harm is rare. Of 991 patients who received corticosteroid injections across the reviewed trials, one (0.1%) had a serious adverse event⁷. The problem with cortisone here is not danger; it is that the benefit is borrowed from the following year
2. This finding is site-specific. The review's authors warn explicitly that response to injection should not be generalised across different tendons. The reversal is well documented at the elbow. Extending it to every tendon in the body goes beyond what the evidence supports⁷

Cortisone doesn't heal the tendon. It suppresses pain while the underlying tissue change continues — and in this particular condition, the trials suggest it interferes with a recovery that would mostly have happened anyway.

Understanding Elbow Tendinopathy: Degeneration, Not Inflammation

The Tendinopathy Spectrum

Despite the historical name "tendinitis" (suggesting inflammation), the histopathology is primarily degenerative — tendinopathy, not tendinitis³. Biopsy studies of chronically painful tendons show:

This matters clinically for one reason: it explains why anti-inflammatory treatment addresses a process that is largely not there, and why the treatments with the best long-term record are the ones that load the tendon rather than quiet it.

It does not, by itself, prove that any particular regenerative injection works. "The tissue is degenerate, therefore a regenerative product will fix it" is a plausible hypothesis, not a result. The results are in the sections below, and they are more modest than the mechanism suggests.

Types of Elbow Tendinopathy

Lateral Epicondylitis (Tennis Elbow)

• Affects the common extensor origin on the outer elbow
• Primarily involves the extensor carpi radialis brevis (ECRB) tendon
• Population prevalence of definite lateral epicondylitis: 1.3%, peaking at ages 45–54¹
• Despite the name, only a small minority of cases arise from tennis

Medial Epicondylitis (Golfer's Elbow)

• Affects the common flexor-pronator origin on the inner elbow
• Population prevalence 0.4% — roughly one case for every three lateral cases¹
• Associated with occupational overuse, throwing sports, and golf

Distal Biceps Tendinopathy

• Affects the biceps tendon insertion at the radial tuberosity
• Less common but increasingly recognised in active individuals

What Actually Raises Your Risk — And What You Can Change

The same population study that produced the prevalence figures also identified the determinants, and several are modifiable¹:

Smoking status, body weight and how work loads are distributed across a day are not usually presented as tennis-elbow interventions. On the evidence, they are among the few things a patient controls directly — and none of them costs anything.

What the Research Says: Regenerative Medicine for Elbow Tendinopathy

The Systematic Review Evidence

One genuine systematic review of injection therapy for this condition exists in the literature cited here, and it is the correct place to start — before any individual study.

Krogh et al. (2013)⁸ — systematic review and network meta-analysis of 17 randomised controlled trials, 1,381 participants, comparing eight injection treatments:

Three things follow from this table, and we are stating all three because two of them are inconvenient for us:

1. ✅ PRP is statistically superior to placebo. That is a real placebo-controlled signal, and it is the strongest single piece of evidence on this page
2. ⚠️ Only 3 of the 17 trials (18%) were at low risk of bias — and none of them were the PRP trials. The low-risk criteria were met by the prolotherapy and polidocanol studies
3. ⚠️ Prolotherapy and hyaluronic acid both scored larger effects than PRP. Neither is a fashionable treatment, and neither is what this clinic sells. The effect sizes are what they are

The review's own conclusion, verbatim: "a paucity of evidence from unbiased trials on which to base treatment recommendations regarding injection therapies for lateral epicondylitis."

That is the honest headline for this entire section.

PRP vs. Corticosteroid — And Why the Comparator Matters

Read the comparator column before the finding column. It is the most important thing on this page.

Peerbooms and Gosens are good trials. They are also the same 100 patients reported twice, and neither has a placebo arm — both randomise PRP against corticosteroid. But this page has already established, from Coombes^6,7, that corticosteroid produces worse one-year outcomes than a placebo injection.

Outperforming a treatment that underperforms placebo does not, by itself, demonstrate benefit over placebo. Against a natural history in which 83–96% of untreated patients recover^4,5,6, a PRP "success" rate of 73% — where success was defined as a 25% or greater reduction in VAS or DASH without reintervention, a considerably weaker bar than "complete recovery or much improvement" — cannot carry the weight it is usually given.

The placebo-controlled case for PRP rests on Krogh's pooled estimate⁸, not on these two reports. That estimate is favourable. It is also built on trials the reviewers judged to be at high or unclear risk of bias.

MSC Therapy for Lateral Epicondylitis: Where It Genuinely Stands

The human evidence is one study of twelve people with no control group.

Lee et al. (2015)¹³ injected allogeneic adipose-derived mesenchymal stem cells, mixed with fibrin glue, under ultrasound guidance into the common extensor tendon lesions of 12 participants with chronic lateral epicondylosis refractory to conservative treatment. Six received 10⁶ cells; six received 10⁷. At 52 weeks:

• VAS pain 66.8 ± 14.5 mm → 14.8 ± 13.1 mm
• Modified Mayo elbow performance index 64.0 ± 13.5 → 90.6 ± 5.8
• Tendon defect areas on ultrasound significantly decreased
• No significant adverse effects through 52 weeks

The authors describe it accurately as "the first [clinical study] to reveal therapeutic value of mesenchymal stem cell injection for treating chronic tendinopathy." First-in-human. Twelve patients. No comparison group of any kind.

And a systematic review has since assessed this literature and did not recommend the treatment. Pas et al. (2017), in the British Journal of Sports Medicine, reviewed stem cell therapy across tendon disorders and concluded that the use of stem cell therapy for tendon disorders in clinical practice is currently not advised — the paper's title is "No evidence for the use of stem cell therapy for tendon disorders: a systematic review"¹⁴.

We offer this treatment. We are also telling you what the review of it says, because you cannot give informed consent to something whose evidence base has been described to you selectively.

Our position, stated plainly: the mechanism is coherent, the 12-patient safety signal was clean, the structural changes on imaging were real, and we think it is worth doing for a specific and narrow group of patients who have exhausted the alternatives. That is a judgement about promise, not a claim of proof. If you want a treatment with placebo-controlled evidence behind it in this condition, the honest answers are a progressive loading programme, time, and — on the pooled data — possibly PRP.

Cell Source Considerations

Where regenerative approaches are used for elbow tendinopathy, they draw on:

1. Mesenchymal stem cells (MSCs) — capable of tenogenic differentiation and release of trophic factors in laboratory and animal models; the clinical evidence in tendon is the single pilot above¹³
2. PRP (platelet-rich plasma) — concentrates platelet-derived growth factors (PDGF, TGF-β, VEGF) that participate in the repair cascade; the best-evidenced of the injectables here^8,9,10
3. Bone marrow aspirate — contains both platelet-rich plasma and mononuclear cells; the single-arm study above reported large short-term improvement in previously untreated patients¹²

Combination protocols are used on the reasoning that PRP creates a more favourable environment for cell survival. That reasoning has not been tested against a control in this condition.

Academic Perspective

What is well established:

• Chronic elbow tendinopathy is a degenerative, not inflammatory, process³
• Corticosteroid injection helps substantially in the short term and produces worse outcomes at 6–12 months than placebo injection or no intervention^4,5,6,7
• Most cases resolve without active treatment within a year^4,5,6
• Progressive loading-based rehabilitation is the best-supported active treatment^4,5

What is supported but uncertain:

• PRP is superior to placebo in pooled analysis (SMD −1.13) and superior to corticosteroid in a 100-patient randomised trial at 1 and 2 years — but rests on trials mostly at high or unclear risk of bias, and its pooled effect is smaller than prolotherapy's and hyaluronic acid's^8,9,10

What is not established:

• MSC therapy for tendon disorders. A systematic review found the evidence insufficient to advise its use in clinical practice¹⁴. The supporting human data in lateral epicondylosis is a single uncontrolled 12-patient pilot¹³
• Optimal cell source, dose, and injection technique — undetermined
• Any outcome beyond two years, for any regenerative option, in this condition

Structural limitations across the whole regenerative literature here: sample sizes of 12 to 100; two of the four studies above have no control group at all; one had its control group dissolve; the only randomised trial uses an active comparator that performs worse than placebo. No placebo-controlled trial of MSC therapy in elbow tendinopathy has been published.

Treatment Options Compared

Conservative Management

Note the top two rows. The two best-supported options on this entire page are exercise and time. We would rather you know that from us than discover it later.

Injection Options

Surgical Options

Surgery is considered only after prolonged failure of everything above. Reported success rates vary widely between series and are not drawn from the randomised literature cited on this page; discuss specific figures with an upper-limb surgeon.

Is Regenerative Therapy Right for You?

Strong Candidates

• Chronic lateral or medial epicondylitis lasting 6+ months — long enough that the natural recovery described at the top of this page has already failed to occur
• Completed a genuine progressive loading programme without adequate benefit
• Failed or only temporarily relieved by cortisone injection
• MRI or ultrasound showing tendon degeneration without complete tear
• Understands and accepts that the MSC evidence base is a single uncontrolled 12-patient study and that a systematic review does not currently advise the treatment^13,14

May Still Benefit

• Partial tendon tears (less than 50% thickness)
• Recurrent tendinopathy after previous surgical repair
• Occupational tendinopathy in workers genuinely unable to modify their activities
• Any of the above, combined with — never instead of — a structured loading programme

Poor Candidates

• Complete tendon rupture requiring surgical repair
• Active infection at or near the injection site
• Unstable elbow joint with ligamentous laxity
• Fluoroquinolone-associated tendinopathy, or tendinopathy secondary to another systemic condition
• Symptoms of less than three months' duration. On the evidence above, most of these resolve without any injection. We will tell you to wait

Decision Framework

What to Expect: The Treatment Journey

Our 7-Day Protocol

Phase 1: Assessment & Preparation (Day 1-2)

• Comprehensive elbow evaluation with high-resolution ultrasound and MRI review
• Grip strength testing and functional assessment
• Review of what has already been tried, and for how long — including whether a genuine loading programme has been completed
• Medical history review and treatment planning

Phase 2: Treatment (Day 3-4)

• Ultrasound-guided injection into the degenerative tendon zone
• Concurrent PRP delivery
• Post-injection protocol initiation

Phase 3: Recovery & Education (Day 5-7)

• Guided progressive loading instruction — this is not optional, and it is the component with the strongest evidence behind it^4,5
• Activity modification guidelines and ergonomic assessment
• Smoking cessation and weight discussion where relevant, given the risk-factor data¹
• Follow-up imaging and progress review
• Comprehensive home exercise programme

Recovery Timeline

Individual recovery varies substantially. This timeline reflects the follow-up schedule used in the published studies^9,13 and what we plan around — not a promised outcome.

Additional Therapies

We offer several adjuncts alongside the core protocol. Their evidence differs enormously and we are not going to present them as equivalent.

• Shockwave therapy (ESWT) — this has a genuine evidence base of its own in tendinopathy for symptom improvement, and it appears in the conservative-management table above for that reason. It is a legitimate standalone treatment, not an upgrade. If ESWT is appropriate for you, it is appropriate whether or not you have an injection. The proposed mechanism — mechanotransduction and angiogenesis — remains preclinical
• Structured loading programme — the best-evidenced component of anything we do for this condition^4,5
• Massage and manual therapy — reasonable for comfort and for compensatory muscle tension in the forearm and shoulder girdle. No evidence that it alters tendon healing
• IV NAD+ infusion and exosome therapy — these are offered as part of our general wellness protocols. There is no published evidence that either improves tendon healing, and we make no such claim. If you are here for your elbow, neither is a reason to choose one option over another

Frequently Asked Questions

Q: Will my tennis elbow get better if I do nothing?

A: Probably, if you can wait. In randomised trials, 83% of patients on a wait-and-see policy and 96% of patients given a placebo injection had recovered or much improved at one year^4,6. That is the single most important fact about this condition and it is why we screen out recent-onset cases. The people for whom active treatment makes sense are those for whom that year has already gone by.

Q: How is regenerative therapy different from cortisone injections?

A: Cortisone suppresses pain effectively for around six weeks and then, in this condition, is associated with worse outcomes at one year than a placebo injection and higher recurrence^6,7. Regenerative injections aim to stimulate repair rather than suppress symptoms. For PRP there is pooled evidence of superiority over placebo, though from trials mostly at high risk of bias⁸. For MSCs the human evidence is a single uncontrolled pilot¹³.

Q: Can stem cells actually repair a damaged tendon?

A: Not proven. MSCs can differentiate toward tenocyte-like cells and secrete trophic factors in laboratory and animal models, and the one human pilot study in this condition reported reduced tendon defect area on ultrasound alongside symptom improvement in 12 patients¹³. But a systematic review of stem cell therapy across tendon disorders concluded that its use in clinical practice is currently not advised¹⁴. Anyone who tells you tendon regeneration by stem cells is established is going beyond the evidence.

Q: You sell this treatment. Why are you arguing against it?

A: We are not arguing against it — we are describing it accurately. We think MSC therapy is a defensible option for a narrow group of patients with genuinely chronic, genuinely refractory tendinopathy who have understood that the evidence is early. That is a real clinical position. It is not the same as a proven treatment, and a page that blurred the two would not help you decide.

Q: How many injections will I need?

A: Most patients receive one treatment session. Some with severe degeneration may be offered a second at 6-12 months. The published studies administered a single injection and followed patients to 52 weeks^9,13; there is no trial evidence on repeat dosing in this condition.

Q: I've had multiple cortisone injections already. Can I still benefit?

A: Possibly, and prior cortisone does not exclude you. But be aware that the evidence points the other way from the usual reassurance: repeated corticosteroid injection is associated with higher one-year recurrence and worse long-term outcomes^6,7, so a history of multiple injections describes a group with a more difficult course, not an especially responsive one. We will want to know how many, how recently, and what happened after each.

Q: Is there any downtime after treatment?

A: Avoid heavy gripping and lifting for 2-4 weeks. Most patients return to desk work within days and resume sport and heavy activity around 6-8 weeks, guided by symptoms. This is considerably less downtime than surgical options.

Q: What about De Quervain's tenosynovitis — does this apply?

A: De Quervain's affects the wrist tendons rather than the elbow, and the evidence reviewed on this page does not transfer to it — the injection review cited here warns specifically that findings should not be generalised between tendon sites⁷. Our wrist and hand article covers that condition separately.

Take the Next Step

Want an honest assessment of whether regenerative therapy is worth considering for your elbow?

• Take our 2-minute Joint Health Assessment
• Book a Discovery Consultation with our regenerative medicine specialists

Our team will review your imaging, your history, and how long you have had symptoms. If you have had elbow pain for less than three months, or have not yet completed a proper loading programme, we will tell you to do that first.